Back

dr. R.P. (Richard) Meijer

dr. R.P. (Richard) Meijer

Associate Professor - medical
dr. R.P. (Richard) Meijer
  • Department of Urological Oncology

Research Programs

Cancer

Biography

Biography

Current positions

2018-present    Associate Professor Oncological Urology, UMC Utrecht

2018-present    Head Department Oncological Urology, UMC Utrecht Cancer Center 

2012-present    Oncological Urologist, University Medical Center Utrecht (UMCU), The Netherlands

2016-present    Deputy Chief of the Specialist Medical Training Urology UMC Utrecht

2016-present    Chairman of the Oncological Urology Tumour Group, UMCU Cancer Center

2016-present    Member of the Oncology Committee, UMCU Cancer Center

2016-present    Associate member of ERUS (EAU Robotic Urology Section)

2015-present    Member of the Dutch Uro-Oncological Society (DUOS)

2015-present    Member Workgroup Oncological Urology (WOU) of the Dutch Urological Association                (Dutch: NVU)

2015                 SKMS workgroup Laparoscopy and Robotic Surgery

2014-present    Associate member of ESOU (EAU Section of Oncological Urology)

2011-present    Editorial Board Dutch Journal of Urology (Dutch: Tijdschrift voor Urologie)

Prior positions

2010-2012       Fellowship Oncological Urology, NKI-AVL, Amsterdam, The Netherlands; Supervisor Prof. Dr. S. Horenblas

Oct 2009          Fellowship Laparoscopy, Universitäts Klinikum Leipzig, Germany; Supervisor Prof. Dr. J.U. Stolzenburg

2008-2009       Resident in Urology, University Medical Center Utrecht, The Netherlands; Supervisor Prof. Dr. J.L.H.R. Bosch

2006-2007       Resident in Urology, JBZ, ’s-Hertogenbosch; Supervisor Dr. H.P. Beerlage

2004-2005       Resident in Surgery, Diakonessenhuis Utrecht, Supervisor Dr. G.J. Clevers

 

Current research projects

Research support (institutional)

  • Janssen (Research-grant) (2017-2022)
  • Roche (Research-grant) (2017-2021)
  • Astellas (Research-grant) (2021-2022)
  • Merck (Educational-grant) (2022)
  • Janssen/Astellas/AstraZeneca/MSD/BMS/Roche/Merck (ProBCI support) (2018---)

Company Advisory Boards (institutional):

  • Merck
  • MSD
  • Janssen
  • Bristol-Myers Squibb Company

2023 Framingham selection Urothelial Cancer Issues (Bristol-Myers Squibb Company; institutional)

Side Activities

  1. Afdelingshoofd Oncologische Urologie
  2. Voorzitter UMC Utrecht Expertise Centrum voor testiculaire en extragonadale kiemceltumoren (Zaadbalkanker)
  3. Panellid EAU Richtlijn Spierinvasief en Gemetastaseerd Blaaskanker
  4. ProBCI Stuurgroep (probci.nl)
  5. BlaZIB Stuurgroep (Blaaskankerzorg in Beeld) (IKNL)
  6. Plaatsvervangend opleider Urologie UMCU
  7. Voorzitter tumorwerkgroep Oncologische Urologie UMCU
  8. Lid Oncologie commissie UMCU Cancer Center
  9. Lid Werkgroep Oncologische Urologie (WOU) van de NVU
  10. Associate member ESOU
  11. Associate member ERUS

Research Output (119)

Voorwoord bij het themanummer ‘Kiemceltumoren’

Boormans Joost L., Meijer Richard P. Oct 2023, In: Tijdschrift voor Urologie. 13 , p. 123 1 p.

Deep learning based correction of RF field induced inhomogeneities for T2w prostate imaging at 7 T

Harrevelt Seb D, Meliado Ettore F M, van Lier Astrid L H M W, Reesink Daan, Meijer Richard P, Pluim Josien P W, Raaijmakers Alexander J E 25 Aug 2023, In: NMR in Biomedicine. 36

Real-world outcomes of first-line chemotherapy for unresectable stage III and IV bladder cancer

Reesink Daan J., van Melick Harm H.E., van der Nat Paul B., Los Maartje, Horenblas Simon, van de Garde Ewoudt M.W., Biesma D. H., Stijns P. E.F., Lavalaye J., De Bruin P. C., Peters B. J.M., Somford D. M., Berends M., Richardson R., Van Andel G., Klaver O. S., Haberkorn B. C.M., Van Rooijen J. M., Korthorst R. A., Meijer R. P., Van der Voort Van Zyp J. R.N., Jun 2023, In: World Journal of Urology. 41 , p. 1551-1562 12 p.

The prevalence and intensity of late effects in patients with testicular germ cell tumors:A first step of instrument development using a stepwise approach

Enzlin Roos, Vervoort Sigrid C.J.M., Suelmann Britt B.M., Meijer Richard P., Teunissen Saskia C.C.M., Zweers Danielle Jun 2023, In: European Journal of Oncology Nursing. 64 , p. 1-8

Minimum Volume Standards:An Incentive To Perform More Radical Cystectomies?

Nuijens Siberyn T., van Hoogstraten Lisa M.C., Meijer Richard P., Kiemeney Lambertus A., Aben Katja K.H., Witjes J. Alfred May 2023, In: European Urology Open Science. 51 , p. 47-54 8 p.

EffectiveNess of a multimodal preHAbilitation program in patieNts with bladder canCEr undergoing radical cystectomy:protocol of the ENHANCE multicentre randomised controlled trial

Akdemir Emine, Sweegers Maike G., Vrieling Alina, Rundqvist Helene, Meijer Richard P., Leliveld-Kors Annemarie M., Van Der Heijden Antoine G., Rutten Vera C., Koldewijn Evert L., Bos Siebe D., Wijburg Carl J., Marcelissen Tom A.T., Bongers Bart C., Retèl Valesca P., Van Harten Wim H., May Anne M., Groen Wim G., Stuiver Martijn M. 7 Mar 2023, In: BMJ Open. 13

Chemoradiation for muscle-invasive bladder cancer using 5-fluorouracil versus capecitabine:a nationwide cohort study

de Haar-Holleman Amy, van Hoogstraten Lisa M C, C C M Hulshof Maarten, Tascilar Metin, Brück Katharina, Meijer Richard P, Alfred Witjes J, Kiemeney Lambertus A, Aben Katja K H, 1 Mar 2023, In: Radiotherapy & Oncology. 183 , p. 109584

Patient preferences for treatment modalities for localised prostate cancer

Teunissen Frederik R, Hehakaya Charisma, Meijer Richard P, van Melick Harm H E, Verkooijen Helena M, van der Voort van Zyp Jochem R N Mar 2023, In: BJUI compass. 4 , p. 214-222 9 p.

High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer:the phase 1B NABUCCO trial

van Dorp Jeroen, Pipinikas Christodoulos, Suelmann Britt B.M., Mehra Niven, van Dijk Nick, Marsico Giovanni, van Montfoort Maurits L., Hackinger Sophie, Braaf Linde M., Amarante Tauanne, van Steenis Charlaine, McLay Kirsten, Daletzakis Antonios, van den Broek Daan, van de Kamp Maaike W., Hendricksen Kees, de Feijter Jeantine M., Boellaard Thierry N., Meijer Richard P., van der Heijden Toine G., Rosenfeld Nitzan, van Rhijn Bas W.G., Jones Greg, van der Heijden Michiel S. 2023, In: Nature Medicine. 29 , p. 588-592 5 p.

Induction therapy with ipilimumab and nivolumab followed by consolidative chemoradiation as organ-sparing treatment in urothelial bladder cancer:study protocol of the INDIBLADE trial

Stockem C. F., Mellema J. J.J., van Rhijn B. W.G., Boellaard T. N., van Montfoort M. L., Balduzzi S., Boormans J. L., Franckena M., Meijer R. P., Robbrecht D. G.J., Suelmann B. B.M., Schaake E. E., van der Heijden M. S. 2023, In: Frontiers in oncology. 13

All research output

Thank you for your review!

Has this information helped you?

Please tell us why, so that we can improve our website.

Contact

Afspraken

Praktisch

hetwkz.nl uses cookies

This website uses cookies This website displays videos from, among others, YouTube. Such parties place cookies (third-party cookies). If you do not want these cookies, you can indicate that here. We also place cookies ourselves to improve our site.

Read more about the cookie policy

Agree No, rather not